Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

- Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability - Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid CAMBRIDGE, Mass. and CARLSBAD, Calif., July 26, 2021 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer's disease. The study demonstrated robust time and dose dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period.

The release as fetched from its publisher. ionis.com ↗